Abstract
Human genomic enhancement, or HGE, which improves human traits by introducing genetic and epigenetic changes, has garnered a lot of attention in light of the astounding advancement in genome editing techniques, such as CRISPR-Cas9, in recent years. This study combines doctrinal and empirical analysis methods to examine bioethical issues of HGE in China. The literature currently in publication on these issues indicates that the majority of Chinese academics and the general public are enthusiastic about the present and potential future applications of genome editing techniques within the parameters of appropriate ethical guidelines; regrettably, no workable ethical governance framework has been put forth so far. Considering this, this study offers a more comprehensive discussion of ethical policy on HGE and develops a robust ethical framework that addresses three related issues about HGE: (1) approaching the precautionary principle as an overarching benchmark; (2) producing a multi-stakeholder collaborative governance model to promote stakeholder engagement and dialogue; and (3) establishing regional ethics review centers to have an independent review process. This is done in an effort to address ethical concerns and further inform policymaking on HGE in China.